<unk>  is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B).<unk>  is not indicated for the treatment of people with primary central nervous system lymphoma.
Lisocabtagene maraleucel
Ciltacabtagene autoleucel
Amylmetacresol
Palifermin
Idecabtagene vicleucel
Nicogel
Isavuconazonium
Ioxaglic acid